Status:
RECRUITING
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
Lead Sponsor:
AbbVie
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, in...
Eligibility Criteria
Inclusion
- Eastern cooperative oncology group (ECOG) performance of \<= 1.
- Confirmed diagnosis of multiple myeloma (MM) according to the International Myeloma Working Group (IMWG) diagnostic criteria with either newly diagnosed or relapsed or refractory (RR) MM, depending on the substudy.
Exclusion
- Participant who has known active central nervous system involvement of MM.
- Participant who has known active infection as outlined in the protocol.
Key Trial Info
Start Date :
June 30 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2036
Estimated Enrollment :
440 Patients enrolled
Trial Details
Trial ID
NCT06892522
Start Date
June 30 2025
End Date
March 1 2036
Last Update
December 22 2025
Active Locations (23)
Enter a location and click search to find clinical trials sorted by distance.
1
Colorado Blood Cancer Institute /ID# 273129
Denver, Colorado, United States, 80218
2
Winship Cancer Institute of Emory University /ID# 274830
Atlanta, Georgia, United States, 30322
3
Weill Cornell Medical College /ID# 272517
New York, New York, United States, 10065
4
University of North Carolina at Chapel Hill /ID# 274667
Chapel Hill, North Carolina, United States, 27514